Inovio Pharma (INO) Misses Q4 EPS by $1.13
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.12 +0.90%
EPS Growth %: +60.7%
Financial Fact:
License fee and milestone revenue from affiliated entity: 574.6K
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +60.7%
Financial Fact:
License fee and milestone revenue from affiliated entity: 574.6K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Inovio Pharma (NASDAQ: INO) reported Q4 EPS of ($1.45), $1.13 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $1.77 million versus the consensus estimate of $2.84 million.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Jefferies Downgrades Belimo Holding AG (BEAN:SW) (BLHWF) to Hold
- JPMorgan Downgrades Anima Holding SA (ANIM3:BZ) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
